P-207

Safety evaluation of fetal stem cell transplantation in diabetic patients

E. Nasli-Esfahani¹, P. Amini¹, S. Amiri¹, M. Ghodsi¹, N. Mojahed-Yazdi¹, F. Abbasi¹, B. Nikbin², B. Arjmand¹, B. Larijani^1
1 Tehran University of Medical Sciences, Endocrinology and Metabolism Research Center, Tehran, Iran; ² Tehran University of Medical Sciences, Immunogenetic Research Center , Department of Immunology, Tehran, Iran

Background: Rapidly increasing prevalence of diabetes throughout the world shows the importance of searching for new therapies such as stem cell therapy in treatment of diabetic patients. In this study we evaluate safety of fetal stem cells in diabetic patients who had taken transplantation 3 years ago.

Methods: 48 out of 56 patients who have received fetal stem cell transplantation or placebo injection were visited for evaluation of complications. Patients were referred to ophthalmologist and cardiologist for examining retinopathy and cardiovascular diseases. 24 hour urine was tested for evaluation of nephropathy and neuropathy was proved by neuropathic symptoms and loss of 10-g monofilament. History of hospitalization or any other diseases were reported.

Result: There were not any significant differences between diabetes complications of case and control group, but we found that fetal cells caused meningioma in one of the patients who have received fetal cell transplantation.

Conclusion: In conclusion in this study we found that fetal stem cell transplantation is a relatively safe procedure because after 3 years it does not cause life-threatening complications and does not change the rate of complications in diabetic patients.

P-208

The practical and critical instruction for nonhuman primate diabetic models

S. He, Y. Chen, Y. Lu, J. Cheng

Laboratory of Transplant Engineering and Immunology,Regenerative Medicine Research Center,West China Hospital, Sichaun University , Chengdu, China

The potential of nonhuman primate models in diabetes research has been well understood, and numerous investigators from the early 1980s to very recently have used nonhuman diabetes models, in particular, for metabolic disease, islet transplantation and immune tolerance induction. But there are persistent and severe obstacles to the development and application of this models, such as expensive and challenging. Moreover the different modeling methods of diabetes led to different characterizations in the pathological mechanisms, process, and complications of the disease(Table 1). Furthermore, the models should be evaluated by multiplicitas parameters, however there are deficiency of systemic evaluation program in nonhuman primate diabetic models.In this scenario, experimental systemic program that is to provide guidelines for nonhuman primate diabetic models are highly required. Moreover, given the expensive and relatively small population of primate, and some fatal diabetic complications, such as hypoglycaemia, diabetic comas and so on, it is imperative that we carefully manage the care and use of these animals in biomedical research studies. The purpose of the present article is to provide guidelines for nonhuman primate models of diabetes in the development and application, and is not intended as mandatory requirements for clinical accreditation. This review provides a comprehensive view and an extensive analysis of the maintenance and development in nonhuman primate models of diabetes. The article briefly reviews the technical and managerial aspects of nonhuman primate diabetic models, gives a practical and critical instruction (Table 2) for housing and care, behavioral conditioning, routine management, development strategy and modeling diagnose and evaluation, as well as correlated disease control, and provides some guidelines for model selection for various purposes. We hope that this article will benefit biomedical researches on NHP diabetic models, and promote animal welfare.

Parallel poster session 4 - Topic: Clinical islet transplantation

P-207

Safety evaluation of fetal stem cell transplantation in diabetic patients

E. Nasli-Esfahani¹, P. Amini¹, S. Amiri¹, M. Ghodsi¹, N. Mojahed-Yazdi¹, F. Abbasi¹, B. Nikbin², B. Arjmand¹, B. Larijani^1
1 Tehran University of Medical Sciences, Endocrinology and Metabolism Research Center, Tehran, Iran; ² Tehran University of Medical Sciences, Immunogenetic Research Center , Department of Immunology, Tehran, Iran

Background: Rapidly increasing prevalence of diabetes throughout the world shows the importance of searching for new therapies such as stem cell therapy in treatment of diabetic patients. In this study we evaluate safety of fetal stem cells in diabetic patients who had taken transplantation 3 years ago.

Methods: 48 out of 56 patients who have received fetal stem cell transplantation or placebo injection were visited for evaluation of complications. Patients were referred to ophthalmologist and cardiologist for examining retinopathy and cardiovascular diseases. 24 hour urine was tested for evaluation of nephropathy and neuropathy was proved by neuropathic symptoms and loss of 10-g monofilament. History of hospitalization or any other diseases were reported.

Result: There were not any significant differences between diabetes complications of case and control group, but we found that fetal cells caused meningioma in one of the patients who have received fetal cell transplantation.

Conclusion: In conclusion in this study we found that fetal stem cell transplantation is a relatively safe procedure because after 3 years it does not cause life-threatening complications and does not change the rate of complications in diabetic patients.

P-208

The practical and critical instruction for nonhuman primate diabetic models

S. He, Y. Chen, Y. Lu, J. Cheng

Laboratory of Transplant Engineering and Immunology,Regenerative Medicine Research Center,West China Hospital, Sichaun University , Chengdu, China

The potential of nonhuman primate models in diabetes research has been well understood, and numerous investigators from the early 1980s to very recently have used nonhuman diabetes models, in particular, for metabolic disease, islet transplantation and immune tolerance induction. But there are persistent and severe obstacles to the development and application of this models, such as expensive and challenging. Moreover the different modeling methods of diabetes led to different characterizations in the pathological mechanisms, process, and complications of the disease(Table 1). Furthermore, the models should be evaluated by multiplicitas parameters, however there are deficiency of systemic evaluation program in nonhuman primate diabetic models.In this scenario, experimental systemic program that is to provide guidelines for nonhuman primate diabetic models are highly required. Moreover, given the expensive and relatively small population of primate, and some fatal diabetic complications, such as hypoglycaemia, diabetic comas and so on, it is imperative that we carefully manage the care and use of these animals in biomedical research studies. The purpose of the present article is to provide guidelines for nonhuman primate models of diabetes in the development and application, and is not intended as mandatory requirements for clinical accreditation. This review provides a comprehensive view and an extensive analysis of the maintenance and development in nonhuman primate models of diabetes. The article briefly reviews the technical and managerial aspects of nonhuman primate diabetic models, gives a practical and critical instruction (Table 2) for housing and care, behavioral conditioning, routine management, development strategy and modeling diagnose and evaluation, as well as correlated disease control, and provides some guidelines for model selection for various purposes. We hope that this article will benefit biomedical researches on NHP diabetic models, and promote animal welfare.

Parallel poster session 4 - Topic: Clinical islet transplantation